Alignment CEO-linked trust sells 298K ALHC shares

Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported open-market sales of a total of 298,000 shares of common stock on May 11, 2026 through an entity associated with him.

Rhea-AI Filing Summary

Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported open-market sales of a total of 298,000 shares of common stock on May 11, 2026 through an entity associated with him. The transactions were executed at weighted-average prices of $16.8494 and $17.5350 per share, across ranges from $16.22 to $17.70. According to a footnote, the sold shares are held by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee. Following these sales, an indirect holding entry shows 1,508,641 shares and a separate direct holding entry shows 1,784,868 shares owned after the reported transactions. A footnote also provides the date of a Rule 10b5-1 plan adoption as November 21, 2025.

Insider Trade Summary 10b5-1

Net Seller: 298,000 shares

Net Sell 3 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 298,000 shs ($5.03M)

Type	Security	Shares	Price	Value
Sale	Common Stock	280,893	$16.8494	$4.73M
Sale	Common Stock	17,107	$17.535	$300K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,508,641 shares (Indirect, See Footnote); Common Stock — 1,784,868 shares (Direct)

Footnotes (4)

1. F1. Date of Rule 10b5-1 plan adoption: 11/21/2025
2. F2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.22 to $17.16. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. F3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
4. F4. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.22 to $17.70. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Key Figures

Total shares sold: 298,000 shares Weighted-average sale price 1: $16.8494 per share Weighted-average sale price 2: $17.5350 per share +5 more

8 metrics

Total shares sold 298,000 shares Open-market sales of common stock on May 11, 2026

Weighted-average sale price 1 $16.8494 per share Non-derivative open-market sale on May 11, 2026

Weighted-average sale price 2 $17.5350 per share Non-derivative open-market sale on May 11, 2026

Indirect shares held after transaction 1,508,641 shares Indirect ownership through JEK Trust after reported sales

Direct shares held after transaction 1,784,868 shares Direct ownership entry after May 11, 2026

Rule 10b5-1 plan adoption date November 21, 2025 Footnote reference for trading plan adoption

Lower sale price range $16.22–$17.16 Price range for one weighted-average sale block

Higher sale price range $17.22–$17.70 Price range for another weighted-average sale block

Key Terms

Rule 10b5-1 plan, weighted-average price, open-market sale, JEK Trust

4 terms

Rule 10b5-1 plan regulatory

"Date of Rule 10b5-1 plan adoption: 11/21/2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average price financial

"The reported price in column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

JEK Trust financial

"Represents securities held by JEK Trust, dated February 8, 2021"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alignment Healthcare (ALHC) report for John E. Kao?

Alignment Healthcare reported that CEO and director John E. Kao was associated with open-market sales totaling 298,000 shares of common stock on May 11, 2026. The sales were executed through an entity indicated as the JEK Trust, where he serves as trustee.

At what prices were the Alignment Healthcare (ALHC) shares sold in this Form 4?

The filing shows weighted-average sale prices of $16.8494 and $17.5350 per share. Footnotes explain that individual trades occurred in multiple transactions within price ranges of $16.22–$17.16 and $17.22–$17.70, respectively, for the reported blocks.

How many Alignment Healthcare (ALHC) shares did the trust linked to John E. Kao hold after the sales?

After the reported sales, one indirect ownership entry shows the trust-linked position at 1,508,641 shares of Alignment Healthcare common stock. This figure reflects the holding following the May 11, 2026 transactions reported as open-market sales.

What are John E. Kao’s direct holdings of Alignment Healthcare (ALHC) after these transactions?

The Form 4 includes a separate holding line indicating 1,784,868 shares of Alignment Healthcare common stock held directly by John E. Kao after the reported date. This direct position is distinct from the indirect shares held through the JEK Trust.

Was a Rule 10b5-1 trading plan referenced in the Alignment Healthcare (ALHC) Form 4?

Yes. A footnote states “Date of Rule 10b5-1 plan adoption: 11/21/2025.” This indicates a trading plan adoption date associated with the reporting person, though the excerpt does not detail specific plan terms or explicitly link each reported sale to that plan.

How many total shares were sold in the Alignment Healthcare (ALHC) insider transactions?

The transaction summary shows 298,000 shares of Alignment Healthcare common stock were sold in the reported transactions. These are categorized as open-market or private sales of non-derivative common stock, all dated May 11, 2026, by an entity associated with John E. Kao.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CALIFORNIA 92868

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S(1)		280,893	D	$16.8494(2)	1,525,748	I	See Footnote(3)
Common Stock	05/11/2026		S(1)		17,107	D	$17.535(4)	1,508,641	I	See Footnote(3)
Common Stock								1,784,868	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/21/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.22 to $17.16. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.22 to $17.70. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)